Avance Clinical Launches Center to Accelerate Biotech Trials
Avance Clinical has launched an Early Phase Center of Excellence for Biotechs, bundling scientific and regulatory guidance with operational...
Jon Napitupulu
Promising Results for CRB-701 in HNSCC & Cervical Cancers
At the 3.6 mg/kg dose of CRB-701, objective response rates reached 47.6% in head and neck squamous cell carcinoma,...
Olema Oncology Data on Palazestrant Combo for Breast Cancer
In a Phase 1b/2 study of palazestrant plus ribociclib in ER+/HER2- advanced or metastatic breast cancer, the 120 mg...
Oncology Trial Reveals Promising Preliminary Phase 1 Results
In an ongoing Phase 1 trial of 12 patients with metastatic BRCA/PALB2-associated cancers (11 pancreatic ductal adenocarcinoma and one...
IO Biotech Unveils Phase 3 Cylembio Melanoma Trial Results
Cylembio plus pembrolizumab delivered a median progression-free survival of 19.4 months versus 11.0 months with pembrolizumab alone in previously...
RAPT to Report Topline Phase 2 Data for RPT904 in CSU
RAPT Therapeutics will release topline results on Monday from a partner-run Phase 2 trial of RPT904 in chronic spontaneous...
ESMO 2025: Promising RP1/Nivolumab Acral Melanoma Data
RP1 plus nivolumab produced a 44% objective response rate (8/18) in an ad hoc analysis of acral melanoma patients...
CRB-701: Remarkable Clinical Responses in HNSCC Cancers
At the 3.6 mg/kg dose of CRB-701, Corbus reported objective response rates of 47.6% in head and neck squamous...
Olema Announces New Data from Palazestrant Cancer Trial
Median PFS reached 15.5 months in the 120 mg palazestrant cohort across all comers, with 12.2 months among patients...
Disc Medicine Presents New Phase 1b CKD/Anemia Trial Data
Disc Medicine will deliver a full Phase 1b update of DISC-0974 in non-dialysis-dependent chronic kidney disease (NDD-CKD) patients with...